Citadel Advisors’s Melinta Therapeutics MLNT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
– Sell
-56,839
Closed -$30K – 10606
2019
Q4
$30K Buy
56,839
+41,984
+283% +$102K ﹤0.01% 8872
2019
Q3
$57K Sell
14,855
-16,259
-52% -$58.6K ﹤0.01% 8670
2019
Q2
$207K Buy
31,114
+16,324
+110% +$62.1K ﹤0.01% 8143
2019
Q1
$53K Sell
14,790
-363
-2% -$1.97K ﹤0.01% 8801
2018
Q4
$60K Buy
15,153
+2,515
+20% +$32.2K ﹤0.01% 8441
2018
Q3
$250K Sell
12,638
-2,158
-15% -$54.6K ﹤0.01% 7873
2018
Q2
$469K Buy
14,796
+12,421
+523% +$447K ﹤0.01% 6475
2018
Q1
$88K Sell
2,375
-1,373
-37% -$90.3K ﹤0.01% 7755
2017
Q4
$296K Buy
+3,748
New +$277K ﹤0.01% 6490

Citadel Advisors's MLNT Position: Q1 2020 in Review

Citadel Advisors sold out of Melinta Therapeutics (MLNT) in Q1 2020, closing a stake of 56,839 shares — an estimated $30K sold.

Citadel Advisors first reported a position in MLNT in Q4 2017 and held it in 9 quarters. The position peaked at $469K in Q2 2018. 2 funds tracked by Wall St. Rank hold MLNT as of Q1 2020.

  • Citadel Advisors reported no remaining Melinta Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Citadel Advisors sold 56,839 Melinta Therapeutics shares in Q1 2020, an estimated $30K.
  • Citadel Advisors first reported a position in Melinta Therapeutics in Q4 2017 and held it in 9 quarters.
  • Citadel Advisors's Melinta Therapeutics position peaked at $469K in Q2 2018.
  • 2 funds tracked by Wall St. Rank held Melinta Therapeutics as of Q1 2020.

Based on Citadel Advisors's 13F filing for Q1 2020, filed 15 May 2020.